Kexing Biopharm Co., Ltd.SSE: 688136

Shareholders' Inquiry Transfer Plan

Nov 15, 2025 · Issued by Kexing Biopharm Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Nov 15, 2025

On 6ix: 6ix.com/news/shareholders-inquiry-transfer-plan-6

Shareholders' Inquiry Transfer Plan

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Kexing Biopharm Co., Ltd. on 6ix

Earlier from Kexing Biopharm

Announcement on Cancellation of Special Settlement Accounts for Some Raised Fund Financial ProductsNov 13, 2025
Announcement on Convening the Q3 2025 Performance BriefingNov 11, 2025
Kexing Biopharm Showcases Global Strategy and Partnership Opportunities at CPHI Frankfurt 2025Oct 31, 2025
Report for Q3 2025Oct 30, 2025
BioDlink Completes First International Shipment of Bevacizumab to ColombiaOct 27, 2025

Later from Kexing Biopharm

Indicative Announcement on Pricing for Shareholders' Inquiry-based TransferNov 18, 2025
Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 5% Integer MultipleNov 21, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of Ophthalmic Preparation GB10 InjectionDec 9, 2025
Announcement on Renewing Engagement of Accounting FirmDec 16, 2025
Announcement on Estimated Amount of Daily Related Transactions in 2026Jan 1

All Kexing Biopharm news releases

Follow Kexing Biopharm into a list and get an email when it puts out news.

Follow Kexing Biopharm